Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul-Aug;23(4):348-356.
doi: 10.2450/BloodTransfus.875. Epub 2024 Dec 17.

First use of cord blood platelet-rich plasma in the treatment of vulvar lichen sclerosus: a preliminary study towards a randomized controlled trial

Veronica Boero  1 , Carlotta Caia  1 , Giulia E Cetera  1   2 , Elisa Pesce  1 , Serena Uccello  3 , Stefania Villa  4 , Tiziana Montemurro  4 , Larysa Mykhailova  4 , Camilla E M Merli  1 , Ermelinda Monti  1 , Flavia Filippi  5 , Paolo Vercellini  2 , Daniele Prati  4
Affiliations

First use of cord blood platelet-rich plasma in the treatment of vulvar lichen sclerosus: a preliminary study towards a randomized controlled trial

Veronica Boero et al. Blood Transfus. 2025 Jul-Aug.

Abstract

Background: Although topical corticosteroids (TCS) represent first-line treatment for vulvar lichen sclerosus (VLS) and as such should be prescribed to all women at time of diagnosis, approximately 30% of patients do not experience complete symptom resolution following such treatment. TCS may not effectively improve vulvar trophism and elasticity, both of which are crucial for sexual function. Owing to its regenerative and healing properties, cord blood platelet-rich plasma (CB-PRP) may represent an efficacious supplementary therapy, to be administered following first line treatment with TCS. The primary aim of this study was to assess safety and tolerability of CB-PRP in women with VLS.

Materials and methods: This is a pilot study which precedes a randomized controlled trial of CB-PRP vs placebo in women with VLS. Ten consecutive patients with VLS, who had previously undergone standard TCS-treatment, received three vulvar CB-PRP injections monthly. Follow-up was conducted three months after the last injection using vulvoscopy and validated questionnaires to evaluate safety and tolerability, as well as patient satisfaction, symptom improvement, sexual function, psychological well-being, quality of life, frequency of TCS application as a maintenance treatment, vulvar trophism and architectural modifications.

Results: No adverse clinical effects were observed. Five patients (50%) were either satisfied or very satisfied with the procedure, four (40%) were uncertain about their satisfaction with the treatment. One patient (10%) dropped out for personal reasons and was classified as unsatisfied according to an intention-to-treat analysis. At follow-up median numeric rating scale scores were significantly reduced for vulvar burning compared to baseline (p<0.05) there was a trend toward improvement in itching, dyspareunia, and dysuria. A significant improvement in sexual arousal and satisfaction was observed in all treated women (p<0.05).

Discussion: CB-PRP may be a promising treatment for VLS. It appears to be safe and improve symptoms and sexual function.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE OF CONFLICTS OF INTEREST: DP serves as Section Editor in BT and has received travel and research grants, speaking fees, and teaching fees from Diasorin, Diamed, Diatech Pharmacogenetics, Grifols, Immucor, Macopharma, Ortho Clinical Diagnostics, Terumo, Cerus. The other Authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Cord blood collection performed by pricking the umbilical vein
Figure 2
Figure 2
(A, B, C). Separation of platelets from platelet-poor plasma
Figure 3
Figure 3
(A, B, C, D). Differences in vulvar trophism before (A–C) and after treatment (B–D).
See this image and copyright information in PMC

References

    1. Kumar KS, Morrel B, van Hees CLM, van der Toorn F, van Dorp W, Mendels EJ. Comparison of lichen sclerosus in boys and girls: a systematic literature review of epidemiology, symptoms, genetic background, risk factors, treatment, and prognosis. Pediatr Dermatol. 2022;39:400–408. doi: 10.1111/pde.14967. - DOI - PMC - PubMed
    1. Kirtschig G, Becker K, Günthert A, Jasaitiene D, Cooper S, Chi CC, et al. Evidence-based (S3) guideline on (anogenital) lichen sclerosus. J Eur Acad Dermatol Venereol. 2015;29:e1–43. doi: 10.1111/jdv.13136. - DOI - PubMed
    1. Krapf JM, Smith AB, Cigna ST, Goldstein AT. Presenting symptoms and diagnosis of vulvar lichen sclerosus in premenopausal women: a cross-sectional study. J Low Genit Tract Dis. 2022;26:271–275. doi: 10.1097/LGT.0000000000000679. - DOI - PubMed
    1. Lagerstedt M, Karvinen K, Joki-Erkkilä M, Huotari-Orava R, Snellman E, Laasanen SL. Childhood lichen sclerosus - a challenge for clinicians. Pediatr Dermatol. 2013;30:444–450. doi: 10.1111/pde.12109. - DOI - PubMed
    1. Pope R, Lee MH, Myers A, Song J, Abou Ghayda R, Kim JY, et al. Lichen sclerosus and sexual dysfunction: a systematic review and meta-analysis. J Sex Med. 2022;19:1616–1624. doi: 10.1016/j.jsxm.2022.07.011. - DOI - PubMed